Bianca BrundelPrincipal Investigator CVON-DOSIS, Co-coordinator CVON-AFFIP

Brief summary of research over the last five years

Bianca Brundel is currently Established Investigator, funded by the Dutch Heart Foundation and Consortium leader of HALT&REVERSE. She opened up new directions for research on protein homeostasis and the protein quality control system underlying atrial fibrillation with the development of a Drosophila model. She is founder of NYKEN BV (2009), a bio-pharmaceutical company to develop innovative therapies for the treatment of atrial fibrillation, using its proprietary platform of Heat Shock Factor activators.

Bianca Brundel is PI on the CVON project ‘Dosis’ (2015-2019). This project aims to identify determinants for onset of inherited cardiomyopathy. Previously developed innovative experimental model systems, which were successfully utilized in atrial fibrillation and GWAS studies, will be exploited in inherited cardiomyopathy studies. Also the invention on the role of protein quality control system in atrial fibrillation will be expanded to other heart and vascular diseases. Brundel has collaborations with (inter)national top researchers (Stanley Nattel, Ivor Benjamin, Edward O’Brien, Rolf Bodmer).

 


 

Current Positions

Since 2016 Professor at Department of Physiology, VUmc, Amsterdam

Since 2016 Director of the foundation AFIP: Atrial Fibrillation Innovation Platform. www.AFIPonline.org

 


 

Top 5 recent publications

1. Brundel BJJM, …, Nattel S. Induction of heat-shock response protects the heart against atrial fibrillation. Circulation Research, 2006; 99:1394-1402. IF: 10.

2. Zhang D, …, Brundel BJJM: Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for AF. JMCC 2011; 51:381-389. IF: 5.5.

3. Den Hoed M, Eijgelsheim M, Esko T, Brundel BJJM et al. Heart rate-associated loci and their effects on cardiac conduction and rhythm disorders- results from a GWAS in up to 181.171 individuals. Nature Genetics 2013; 45:621-31. IF: 36.

4. Zhang D, .., Brundel BJJM. Activation of Histone Deacetylase-6 (HDAC6) induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human Atrial Fibrillation. Circulation 2014; 129:346-58. IF: 15.

5. Zhang D, Hu X, Henning RH, Brundel BJJM. Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation. Cardiovasc Res. 2016;109:519-26. IF:6. Invited review by S. Nattel.

 


 

Selection of ongoing projects

2016 Cardiovasculair Onderzoek Nederland (CVON) research grant. Atrial Fibrillation FIngerPrinting: Spotting Bio-Electrical Markers to Early Recognize Atrial Fibrillation by the Use of a Bottom-Up Approach (AFFIP). Coordinators: Natasja de Groot (EMC) & Bianca Brundel (VUmc). National consortium grant.

2015  Cardiovasculair Onderzoek Nederland (CVON) research grant. Determinants of susceptibility in inherited cardiomyopathy: towards novel therapeutic approaches. Acronym: Dosis. Coordinators: Jolanda van der Velden & Rudolf de Boer (UMCG). National consortium grant.

2014  Life Science and Health (LSH-TKI) research grant. HSF1 Activators lower cardiomyocyte damage: towards a novel therapeutic approach to reverse atrial fibrillation (HALT&REVERSE) Coordinators: Bianca Brundel (VUmc) & Natasja de Groot (EMC). National consortium grant.

2014  Hartstichting/stichting Hartedroom: ‘Boosting chaperone networks to counteract juvenile DCM caused by chaperone mutations.’ Harrie Kampinga (UMCG) & Bianca Brundel (VUmc).

2014  Hartstichting Established Investigator grant. Reversal of cardiomyocyte structural remodeling remodeling and improvement of functional recovery in atrial fibrillation. Personal grant Bianca Brundel (VUmc).